Havryks-1440

Havryks-1440
  • Contraindication

    Havrix™ should not be administered to individuals with known hypersensitivity to any component of the vaccine, or in the presence of hypersensitivity reactions after previous administration of Havrix™ vaccine.

  • Side effects

    After vaccination, loss of appetite, irritability, drowsiness, nausea, diarrhea, fever, redness, rash, pain and swelling at the injection site may be observed.

    In the presence of mechanical inclusions or a strange color of the solution, the use of the vaccine is unacceptable.

Havryks-1440

1700 UAH
  • Producing country:Belgium
  • Composition and form of release:suspension for injection.

Against what:

Application

Havrix is intended for intramuscular administration. For adults, the vaccine is injected into the area of the deltoid muscle.

Primary vaccination

Adults 19 years of age and older. For the primary immunization of adults, a single dose of Havriks™ 1440 vaccine (adult dose) (1.0 ml of suspension) is used.

Booster vaccination

After the initial vaccination with Havrix™ 1440 (adult dose) to ensure long-term immune protection, it is recommended to administer a booster dose of the vaccine. This booster dose should be given anytime between 6 months and 5 years after the first dose, but preferably between 6 and 12 months after the first dose of vaccine.

  • Indication

    Havrix™ vaccine is intended for active immunization of persons who are at risk of infection with the hepatitis A virus. The vaccine does not prevent infection caused by other pathogens, for example, hepatitis B, hepatitis C, hepatitis E viruses or other pathogens that cause other liver diseases .

    In areas with low and moderate hepatitis A endemicity, it is recommended to immunize with the Havrix™ vaccine first of all persons who constitute or may constitute groups of increased risk of infection.